3 tips for biotech startups seeking non-dilutive capital to survive the downturn

James Coates
Contributor




Share on Twitter





James Coates is the Health and Human Performance principal at Decisive Point, a venture capital and advisory firm that invests in and supports startups with emerging defense technologies.



Future-proofing the finances of your biotech startup through a market collapse means more than just raising capital or rushing to close your round.
I perform due diligence on dozens of life science companies each week whose technologies might help future-proof the world against the next biothreat, p

リンク元